RHOA and Alzheimer disease: We further investigated the role of downregulated RhoA/ROCK1/YAP/F-actin with decreased AoSMC stiffness in AD development using an AD mouse model treated with β-aminopropionitrile (BAPN), a traditional medicine for the pharmaceutical AD model.